Products
Online Inquiry
Fimepinostat
Cat. No.:
0225LY-1294
Purity:
≥99%
Identity:
Confirmed by NMR.
Size:
Add to basket
Product Overview
Description:
Fimepinostat is an orally bioavailable dual inhibitor of pan-HDAC and PI3K class I enzymes that prevents the activation of the PI3K-AKT-mTOR pathway in cancer cells.
Synonym:
CUDC-907; PI3K/HDAC Inhibitor; CUDC 907; 1339928-25-4; CUDC907; PI3K/HDAC Inhibitor; N-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide; N-hydroxy-2-(((2-(6-methoxypyridin-3-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxamide; N-Hydroxy-2-[{[2-(6-methoxypyridin-3-yl)-4-(morpholin-4-yl)thieno[3,2-d]pyrimidin-6-yl]methyl}(methyl)amino]pyrimidine-5-carboxamide
CAS No.:
1339928-25-4
Compound CID:
54575456
Formula:
C23H24N8O4S
Formula Weight:
508.55
Specification
Targets&IC50:
HDAC10: 2.8 nM; HDAC1: 1.7 nM; HDAC2: 5.0 nM; HDAC3: 1.8 nM; HDAC11: 5.4 nM
Relative Density:
1.445 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Fimepinostat can be used in cancer pharmacology to evaluate the synergistic effects of inhibiting both HDAC and PI3K pathways.
Library Information
Target:
PI3K; HDAC
Receptor:
HDAC1; HDAC10; HDAC11; HDAC2; HDAC3; PI3K
Pathways:
Apoptosis; PI3K/Akt/mTOR signaling; Chromatin/Epigenetic; DNA damage/DNA repair
Plate Number:
AOCL-17
Plate Location:
e11
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
62.5 mg/mL; 122.9 mM
Ethanol Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
ALogP:
2.303
HBA_Count:
8
HBD_Count:
1
Rotatable Bond:
7
